CY1116245T1 - Φαρμακευτικη συνθεση η οποια εχει αντιμικροβιακη και ταχεια επουλωτικη δραστικοτητα για εξωτερικη χορηγηση, και διεργασια για την παρασκευη αυτης - Google Patents

Φαρμακευτικη συνθεση η οποια εχει αντιμικροβιακη και ταχεια επουλωτικη δραστικοτητα για εξωτερικη χορηγηση, και διεργασια για την παρασκευη αυτης

Info

Publication number
CY1116245T1
CY1116245T1 CY20151100198T CY151100198T CY1116245T1 CY 1116245 T1 CY1116245 T1 CY 1116245T1 CY 20151100198 T CY20151100198 T CY 20151100198T CY 151100198 T CY151100198 T CY 151100198T CY 1116245 T1 CY1116245 T1 CY 1116245T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
external administration
antimicrobial
protection process
phosphomycin
Prior art date
Application number
CY20151100198T
Other languages
English (en)
Inventor
Konstantin Valentinovich Gaidul
Aleksandr Valerevich Dushkin
Viktor Lvovich Limonov
Original Assignee
Viktor Lvovich Limonov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viktor Lvovich Limonov filed Critical Viktor Lvovich Limonov
Publication of CY1116245T1 publication Critical patent/CY1116245T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση αφορά φαρμακολογία, ιατρική, κτηνιατρική και την φαρμακευτική βιομηχανία, ειδικότερα μια διεργασία για την παρασκευή πρωτότυπων σύνθετων αντιμικροβιακών και ταχέως επουλωτικών παρασκευασμάτων για εξωτερική χορήγηση τα οποία έχουν αυξημένη θεραπευτική αποτελεσματικότητα στη θεραπευτική αγωγή μολύνσεων του δέρματος και των μαλακών ιστών. Η προτεινόμενη φαρμακευτική σύνθεση αποτελείται, ως δραστικό συστατικό, από την αντιβιοτική φωσφομυκίνη και υψηλά διεσπαρμένο νανοκατασκευασμένο διοξείδιο πυριτίου. Η αξιούμενη διεργασία για την παρασκευή μιας φαρμακευτικής σύνθεσης περιλαμβάνει ανάμιξη της ουσίας φωσφομυκίνης με υψηλά διεσπαρμένο νανοκατασκευασμένο διοξείδιο πυριτίου και χαρακτηρίζεται από το ότι το μίγμα των ανωτέρω αναφερόμενων ουσιών σε αναλογίες 25-75% κατά βάρος : 75-25% κατά βάρος υποβάλλεται σε μηχανική επεξεργασία μέσω λείανσης με πρόσκρουση μέχρι η αναλογία του λεπτόκοκκα διεσπαρμένου κλάσματος (≤ 5 μm) να αυξηθεί μέχρι τουλάχιστον 40%.
CY20151100198T 2010-09-20 2015-02-25 Φαρμακευτικη συνθεση η οποια εχει αντιμικροβιακη και ταχεια επουλωτικη δραστικοτητα για εξωτερικη χορηγηση, και διεργασια για την παρασκευη αυτης CY1116245T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EA201001506A EA021875B1 (ru) 2010-09-20 2010-09-20 Фармацевтическая композиция антимикробного и ранозаживляющего действия для наружного применения, способ ее получения
EP11827039.6A EP2476420B8 (en) 2010-09-20 2011-05-11 Pharmaceutical composition having antimicrobial and fast-healing activity for external administration, process for preparing same

Publications (1)

Publication Number Publication Date
CY1116245T1 true CY1116245T1 (el) 2017-02-08

Family

ID=45874028

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100198T CY1116245T1 (el) 2010-09-20 2015-02-25 Φαρμακευτικη συνθεση η οποια εχει αντιμικροβιακη και ταχεια επουλωτικη δραστικοτητα για εξωτερικη χορηγηση, και διεργασια για την παρασκευη αυτης

Country Status (22)

Country Link
US (1) US20130171198A1 (el)
EP (1) EP2476420B8 (el)
JP (1) JP2013537227A (el)
CN (1) CN102811724A (el)
AU (1) AU2011304259C1 (el)
BR (1) BR112012023965A2 (el)
CA (1) CA2780771C (el)
CY (1) CY1116245T1 (el)
DK (1) DK2476420T3 (el)
EA (1) EA021875B1 (el)
ES (1) ES2531586T3 (el)
HR (1) HRP20150112T1 (el)
ME (1) ME02057B (el)
MX (1) MX2012010536A (el)
NZ (1) NZ598833A (el)
PL (1) PL2476420T3 (el)
PT (1) PT2476420E (el)
RS (1) RS53835B1 (el)
SI (1) SI2476420T1 (el)
SM (1) SMT201500048B (el)
UA (1) UA103117C2 (el)
WO (1) WO2012039642A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2476206C1 (ru) 2011-11-22 2013-02-27 Виктор Львович Лимонов Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты)
US10226425B2 (en) * 2013-11-06 2019-03-12 Invenres Gmbh Pharmaceutical preparation and method of its production and use
EP3104874B1 (en) * 2014-02-05 2020-01-01 Reponex Pharmaceuticals A/S Compositions to promote the healing of skin ulcers and wounds
EP3848047A1 (en) 2014-07-24 2021-07-14 Reponex Pharmaceuticals APS Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252859A (en) * 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
IT1243180B (it) * 1990-07-31 1994-05-24 Nunzio Rapisarda Uso della fosfomicina e dei suoi sali come agente cicatrizzante topico
FR2687071B1 (fr) * 1992-02-10 1995-06-23 Exsymol Sa Vecteur pour principe(s) actif(s) therapeutique(s) ou cosmetique(s) a usage externe et composition therapeutique ou cosmetique comprenant un tel vecteur.
JPH09183720A (ja) * 1995-12-28 1997-07-15 Shiseido Co Ltd 医薬用組成物
UA32088C2 (en) * 1998-12-23 2004-07-15 Yurii Mykolaiovych Shevchenko Wound healing preparation and method for its manufacture
EA013864B1 (ru) * 2008-08-29 2010-08-30 Лимонова, Анастасия Викторовна Способ повышения антимикробной активности цефалоспориновых антибиотиков

Also Published As

Publication number Publication date
US20130171198A1 (en) 2013-07-04
EA201001506A1 (ru) 2012-02-28
CA2780771C (en) 2015-12-08
PL2476420T3 (pl) 2015-06-30
EA021875B1 (ru) 2015-09-30
DK2476420T3 (en) 2015-02-16
PT2476420E (pt) 2015-02-13
AU2011304259A1 (en) 2012-04-19
SMT201500048B (it) 2015-05-05
ES2531586T3 (es) 2015-03-17
AU2011304259B2 (en) 2012-06-28
WO2012039642A8 (ru) 2012-09-07
SI2476420T1 (sl) 2015-03-31
MX2012010536A (es) 2012-11-16
AU2011304259A8 (en) 2012-07-05
EP2476420B8 (en) 2015-02-18
EP2476420B1 (en) 2014-11-26
NZ598833A (en) 2015-11-27
EP2476420A4 (en) 2013-04-03
AU2011304259B8 (en) 2012-07-05
AU2011304259C1 (en) 2012-11-29
BR112012023965A2 (pt) 2016-08-02
WO2012039642A1 (ru) 2012-03-29
UA103117C2 (uk) 2013-09-10
RS53835B1 (en) 2015-06-30
EP2476420A1 (en) 2012-07-18
JP2013537227A (ja) 2013-09-30
ME02057B (me) 2015-05-20
CN102811724A (zh) 2012-12-05
CA2780771A1 (en) 2012-03-29
HRP20150112T1 (hr) 2015-05-08

Similar Documents

Publication Publication Date Title
JP6272366B2 (ja) 細菌バイオフィルムの処置および他の使用をはじめとする、生体医学的使用のための消毒薬としてのビスマス−チオール
CY1116245T1 (el) Φαρμακευτικη συνθεση η οποια εχει αντιμικροβιακη και ταχεια επουλωτικη δραστικοτητα για εξωτερικη χορηγηση, και διεργασια για την παρασκευη αυτης
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
JP2013518895A (ja) 細菌バイオフィルムの処置および他の使用をはじめとする、生体医学的使用のための消毒薬としてのビスマス−チオール
BR112015020787A2 (pt) inibidores quinazolínicos de formas mutantes ativantes do receptor do fator de crescimento epidérmico
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BRPI0709581A8 (pt) compostos de bicicloeteroarila como moduladores de px27 e seu uso
MX2013003635A (es) Compuestos de n-heteroarilo.
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
RU2012149863A (ru) Полисахарид семени тамаринда для применения в лечении микробных инфекций
BR112023022496A2 (pt) Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
Azimzadeh et al. Synergistic effects of nano curcumin mediated photodynamic inactivation and nano-silver@ colistin against Pseudomonas aeruginosa biofilms
MX2022001802A (es) Metodos para incrementar la biodisponibilidad de medicamentos farmaceuticos y de venta libre.
BRPI0720251B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo
EP2950804B1 (en) Antibiotic preparation and use thereof
BR112020024261B8 (pt) Composto de fórmula (ia) e composição farmacêutica
BR112012016549A2 (pt) piperazinas como agentes antimalariais
BR112018070064A2 (pt) composições farmacêuticas estáveis para administração tópica e uso das mesmas
EA201100735A1 (ru) Фармацевтическая композиция антибактериального действия для парентерального применения, способ ее получения
CR20220620A (es) Composición farmacéutica acuosa de levilimab y su uso
UA103116C2 (ru) Порошкообразная фармацевтическая композиция антимикробного и противовоспалительного действия для парентерального введения, которая содержит фосфомицин и высокодисперсный наноструктурированный диоксид кремния, способ ее получения
PL431336A1 (pl) Lipopeptydy, kompozycja farmaceutyczna, kompozycja kosmetyczna oraz lipopeptydy do zastosowania jako lek
WO2018067663A3 (en) Ketolides having antibacterial activity